PD-L1

March 13, 2017

BET Inhibitors Bolster Mouse Model’s Immunity Against Lymphoma, Study Shows

News

A new class of therapies called BET inhibitors bolstered anti-tumor immunity in mouse models of lymphoma, offering a promising new approach to enhancing blood cancer therapies, according to a study. Researchers ... Read more

October 7, 2016October 7, 2016

First B-Cell Lymphoma Patients Dosed in Phase 1 Study of Potential Therapy

News

Dosing of patients has begun in a Phase 1 clinical trial evaluating the safety and tolerability of Karus Therapeutics‘ lead anti-cancer candidate, KA2237, as a treatment for B-cell lymphoma, the company announced. The ... Read more

December 8, 2015May 13, 2016

New Non-Hodgkin Lymphoma Drug Combo Trial Launched by Amgen, Merck

News

Amgen and Merck are partnering to support a Phase 1b/3 clinical trial evaluating a cancer immunotherapy combination in patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL). The ... Read more